NEW YORK, Aug. 28 - DNAPrint Genomics today said it will incorporate into certain of its pharmacogenomics and forensics tests a modified DNA made by Danish microarray firm Exiqon.
The technology, called Locked Nucleic Acid, is a DNA analog that is said to have favorable binding affinity toward complementary DNA and the ability to discriminate between matching and mismatching target sequences, according to DNAPrint.
Sarasota, Fla.-based DNAPrint said it hopes the LNA technology will improve the performance of its kits and services. The company did not say how much it paid for the non-exclusive rights to use the LNA.
Exiqon, based in Denmark, is privately held.